Please assess the completion status of the following clinical trial:

Trial Title: Assessment in Work Productivity and the Relationship With Cognitive Symptoms in Patients With MDD Taking Vortioxetine

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* The patient is a man or woman, aged ≥18 years and \<65 years (In the province of British Columbia, the patient must be aged 19 years or older in order to give Informed Consent)~* The patient is engaged in volunteer work or gainful employment (working ≥20 hours per week) or is enrolled full-time in post-secondary studies or vocational training.~* The patient is an outpatient consulting a Primary Care Physician or a Psychiatrist.~* Patients must have a diagnosis of MDD according to the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5™) classification code 296.3x.~* The current MDE is confirmed by the investigator.~* The reported duration of the current MDE is at least 3 months.~* The patient has a Baseline score ≥15 on the QIDS-SR.~* The patient reports at least a minimal level of cognitive symptoms as defined by Baseline score of ≥30 on the PDQ-D-20.~* The patient is capable of communicating with the site personnel and is able to conduct the digit-symbol substitution test (DSST).~Exclusion Criteria:~* The patient score is \>69 on the DSST at Screening/Baseline.~* The patient is, in the opinion of the investigator, not able to complete all the study assessments including, but not limited to, patient-reported assessments and the DSST.~* The patient has a current diagnosis or history of manic or hypomanic episode, schizophrenia or any other psychotic disorder, including major depression with psychotic features.~* The current depressive symptoms are considered by the investigator to have been resistant to 2 adequate antidepressant treatments of at least 6 weeks duration each at the maximum recommended dose (according to Canadian labeling).~Other protocol defined inclusion and exclusion criteria do apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- vortioxetine naive (Type: OTHER): vortioxetine 10 mg 100 patients with Major Depressive Disorder who have not been treated with another antidepressant for the current MDE
- Switch (Type: OTHER): vortioxetine 10 mg 100 patients with Major Depressive Disorder that require a switch from their current antidepressant due to inadequate response

Based on this trial design, predict the completion outcome and termination type (if applicable).